Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Lancet. 2011 Jul 30;378(9789):412-9. doi: 10.1016/S0140-6736(11)60886-6. Epub 2011 Jun 28.

Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial.

Collaborators (295)

Skyler JS, Anderson M, Bourcier K, Becker D, Bingley P, Blum J, Bosi E, Buckner J, Chase HP, Clare-Salzler M, Colman P, DiMeglio L, Eisenbarth GS, Fathman CG, Gitelman S, Goland R, Gottlieb P, Grave G, Greenbaum C, Harrison L, Herold K, Insel R, Krischer JP, Mahon J, Marks J, Moran A, Palmer JP, Peakman M, Pugliese A, Raskin P, Roncarolo MG, Russell W, Savage P, Schatz D, Sherwin R, Siegelman M, Simell O, Thomas J, Trucco M, Wagner J, Wherrett D, Wilson DM, Winter W, Fradkin J, Leschek E, Spain L, Benoist C, Bluestone J, Brown D, Cowie C, Hering B, Jordan S, Kaufman FR, Lachin JM, Nanto-Salonen K, Nepom G, Orban T, Parkman R, Pescovitz M, Peyman J, Ridge J, Rodriguez H, Ziegler A, Skyler JS, Bourcier K, Greenbaum CJ, Krischer JP, Leschek E, Rafkin L, Savage P, Spain L, Cowie C, Foulkes M, Krause-Steinrauf H, Lachin JM, Malozowski S, Peyman J, Ridge J, Zafonte SJ, Skyler JS, Greenbaum CJ, Kenyon NS, Rafkin L, Santiago I, Sosenko JM, Krischer JP, Ritzie AL, Bundy B, Abbondondolo M, Adams T, Alies P, Badias F, Beam C, Boonstra M, Boulware D, Cuthbertson D, Eberhard C, Ford J, Ginem J, Guillette H, Hays B, Henry M, Law P, Linton C, Liu S, Lloyd J, Muller S, O'Donnell R, Parrimon Y, Paulus K, Pilger J, Ramiro J, Roberts A, Sadler K, Terry A, Wootten M, Xu P, Young K, Bassi M, Freeman D, Granger M, Kieffer M, Nallamshetty L, Shor A, Lachin JM, Foulkes M, Harding P, Krause-Steinrauf H, McDonough S, McGee PF, Hess KO, Phoebus D, Quinlan S, Raiden E, Fradkin J, Leschek E, Savage P, Spain L, Blumberg E, Braun J, Laffel L, Naji A, Nerup J, Orchard T, Tsiatis A, Veatch R, Wallace D, Lernmark A, Lo B, Mitchell H, Steffes M, Zinman B, Loechelt B, Baden L, Green M, Weinberg A, Babu S, Eisenbarth GS, Marcovina S, Palmer JP, Weinberg A, Winter W, Yu L, Orban T, Gottlieb P, Greenbaum C, Krause-Steinrauf H, Lachin JM, Leschek E, Loechelt B, Parkman R, Rafkin L, Rigby A, Skyler JS, Spain L, Wagner J, Greenbaum C, Bollyky J, Sanda S, Tridgell D, McCulloch-Olson M, Vendettuoli H, Hefty D, Ramey M, Webber C, Kuhns K, Hilderman N, Dove A, Hammond M, Klein J, Batts E, Monzavi R, Halvorson M, Bock M, Fisher L, Jeandron D, Wood J, Kaufman FR, Goland R, Greenberg E, Gallagher MP, Trast J, Chan M, Rodriguez H, Pescovitz M, DiMeglio L, Christner L, Nicholson M, Mendez M, Orban T, Benoist C, Wolfsdorf J, Ricker A, Jalahej H, Conboy D, Farkas K, Kis J, Zhang H, Fay S, Wilson DM, Buckingham BA, Aye T, Esrey T, Soto A, Perry J, Baker B, Rigby A, Berry B, Gitelman SE, Rosenthal SM, Anderson M, Adi S, Breen K, Hamilton C, Gottlieb P, Chase HP, Michels A, Kastelic W, Weiner L, Schatz D, Haller M, Clare-Salzler M, Cook R, Mancini D, Abraham A, Hicks E, Cole G, Marks JB, Pugliese A, Matheson D, Blaschke C, Arazo L, Cisneros M, Acosta B, Moran A, Nathan B, Wagner J, Boes MA, Gibson C, Finney L, Albright-Fischer T, Smith J, Becker D, Toledo F, Libman I, Riley K, Delallo K, Smith K, Gwynn D, Wohlers G, Raskin P, White P, Dickson B, Adhikari S, Siegelman M, Alford M, Torres N, Harden T, Pruneda L, Cordova E, Davis R, Fernandez S, Arthur J, Wherrett D, Eisel LA, Ahenkorah B, Razack N, Sriskandarajah M, Russell WE, Thomas JW, Moore DJ, Brown A, Black M, Pittel E, Brendle F.

Author information

  • 1Joslin Diabetes Center, Boston, MA, USA.

Abstract

BACKGROUND:

The immunopathogenesis of type 1 diabetes mellitus is associated with T-cell autoimmunity. To be fully active, immune T cells need a co-stimulatory signal in addition to the main antigen-driven signal. Abatacept modulates co-stimulation and prevents full T-cell activation. We evaluated the effect of abatacept in recent-onset type 1 diabetes.

METHODS:

In this multicentre, double-blind, randomised controlled trial, patients aged 6-45 years recently diagnosed with type 1 diabetes were randomly assigned (2:1) to receive abatacept (10 mg/kg, maximum 1000 mg per dose) or placebo infusions intravenously on days 1, 14, 28, and monthly for a total of 27 infusions over 2 years. Computer-generated permuted block randomisation was used, with a block size of 3 and stratified by participating site. Neither patients nor research personnel were aware of treatment assignments. The primary outcome was baseline-adjusted geometric mean 2-h area-under-the-curve (AUC) serum C-peptide concentration after a mixed-meal tolerance test at 2 years' follow-up. Analysis was by intention to treat for all patients for whom data were available. This trial is registered at ClinicalTrials.gov, NCT00505375.

FINDINGS:

112 patients were assigned to treatment groups (77 abatacept, 35 placebo). Adjusted C-peptide AUC was 59% (95% CI 6·1-112) higher at 2 years with abatacept (n=73, 0·378 nmol/L) than with placebo (n=30, 0·238 nmol/L; p=0·0029). The difference between groups was present throughout the trial, with an estimated 9·6 months' delay (95% CI 3·47-15·6) in C-peptide reduction with abatacept. There were few infusion-related adverse events (36 reactions occurred in 17 [22%] patients on abatacept and 11 reactions in six [17%] on placebo). There was no increase in infections (32 [42%] patients on abatacept vs 15 [43%] on placebo) or neutropenia (seven [9%] vs five [14%]).

INTERPRETATION:

Co-stimulation modulation with abatacept slowed reduction in β-cell function over 2 years. The beneficial effect suggests that T-cell activation still occurs around the time of clinical diagnosis of type 1 diabetes. Yet, despite continued administration of abatacept over 24 months, the decrease in β-cell function with abatacept was parallel to that with placebo after 6 months of treatment, causing us to speculate that T-cell activation lessens with time. Further observation will establish whether the beneficial effect continues after cessation of abatacept infusions.

FUNDING:

US National Institutes of Health.

Copyright © 2011 Elsevier Ltd. All rights reserved.

Comment in

PMID:
21719096
[PubMed - indexed for MEDLINE]
PMCID:
PMC3462593
Free PMC Article

Publication Types, MeSH Terms, Substances, Secondary Source ID, Grant Support

Publication Types

MeSH Terms

Substances

Secondary Source ID

Grant Support

PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Icon for Elsevier Science Icon for PubMed Central
    Loading ...
    Write to the Help Desk